Tiger Pharma: Subsidiary and Kyusek Pharmaceuticals established the United States FJ Company to provide drug research and development one-stop service

Tiger Pharma announced on the evening of January 24th that Frontage Laboratories, Inc., a subsidiary of the company, had announced that it would not be in a company that would be in a state of force. ("Fangda Pharmaceuticals") recently signed a Letter of Intent on the Establishment of a Joint Venture with Zhejiang Jiuzhou Pharmaceutical Co., Ltd. ("Kyuszhou Pharmaceuticals"), and the two sides intend to fund the establishment of the U.S. FJ Company (tentatively named, based on the name of the company's final establishment).
FJ company, which is to be established, will provide a one-stop service for drug research and development to pharmaceutical companies in the United States and other countries and regions. The company has a registered capital of US$2 million, of which Fangda Pharmaceuticals contributed US$980,000, accounting for 49% of FJ Corporation of the United States, and Kyuszhou Pharmaceuticals contributed US$1.02 million, accounting for 51% of FJ Corporation of the United States.
Jiuzhou Pharmaceuticals is a specialty API and intermediates and patented pharmaceutical raw materials and intermediates research and development, production and sales as one of the national technology innovation demonstration enterprises, built a national recognized enterprise technology center, the national postdoctoral research workstation, the main products include the central nervous system, anti-infection, cardiovascular and other therapeutic fields of drugs.
announcement said there was no association between Tiger Pharma and Fangda Pharmaceuticals and Kyusah Pharmaceuticals' controlling shareholders, actual controllers and directors, supervisors and senior management.
Teg Pharmaceuticals said that the joint venture with Kyusah Pharmaceuticals is intended to fully combine and play their respective advantages, on the one hand, Fangda Pharmaceutical will have the opportunity to expand customer resources, looking for new business opportunities, on the other hand, Kyuschu Pharmaceuticals will play its advantages in chemical synthesis, process development and production to provide customers with more comprehensive services.
at the same time, Tiger Pharmaceuticals said that the cooperation will not have a significant impact on the normal production and operation and performance of the company and Fangda Pharmaceuticals, nor will it affect the company's business independence. (Securities Times Network)